Anticoagulants and antithrombotic drugs have played a key role in the prophylaxis, treatment and surgical/interventional management of thrombotic and cardiovascular disorders. There are several newer drugs which are currently developed for the anticoagulant management of cardiovascular diseases in both the medical and surgical indications. These include the low molecular weight heparins (LMWHs), antithrombin agents such as the Hirudin, Hirulog and Argatroban and indirect and direct anti-Xa drugs, represented by Pentasaccharide (Arixtra®) and DX 9065a, respectively. Several other agents such as the natural and recombinant anti-Xa drugs and anti-tissue factor agents are also developed. The antiplatelet agents include Clopidogrel, Cilostazol, Anplag and GP Ilb/Illa inhibitors. For the subcutaneous indications, unfractionated heparin is gradually replaced by the low molecular weight heparins (LMWHs). LMWHs such as the Enoxaparin and Dalteparin are commonly used for the management of acute coronary syndrome. These drugs have been approved for the treatment of unstable angina and are currently undergoing rigorous trials for interventional indications. Arixtras is also developed for various subcutaneous indications. However, it exhibits lower anticoagulant effects and may not be optimal for intravenous and interventional purposes. At a higher dosage when administered intravenously the LMWHs produce varying degrees of anticoagulation at relatively lower activated clotting times . Several studies in vascular and cardiovascular interventions have shown that even at a relatively lower anticoagulant level the LMWHs are as effective as unfractionated heparin at the recommended dosages which produce a relatively higher level of anticoagulation (ACT > 200 secs.). Thus, these agents are currently developed for interventional and surgical indications. It should be emphasized that different LMWHs produce different degrees of anticoagulation and should therefore be individually optimized for a given interventional or surgical purposes. At a relatively high dosage the levels of LMWHs can be measured by using the ACT and APTI. When administered with such GP Ilb/Illa inhibitors as the Abciximab, Aggrastat or Eptifibratide, these drugs may require dosage adjustment.
Summary: Anticoagulants and antithrombotic drugs have played a key role in the prophylaxis, treatment and surgical/interventional management of thrombotic and cardiovascular disorders. There are several newer drugs which are currently developed for the anticoagulant management of cardiovascular diseases in both the medical and surgical indications. These include the low molecular weight heparins (LMWHs), antithrombin agents such as the Hirudin, Hirulog and Argatroban and indirect and direct anti-Xa drugs, represented by Pentasaccharide (Arixtra®) and DX 9065a, respectively. Several other agents such as the natural and recombinant anti-Xa drugs and anti-tissue factor agents are also developed. The antiplatelet agents include Clopidogrel, Cilostazol, Anplag and GP Ilb/Illa inhibitors. For the subcutaneous indications, unfractionated heparin is gradually replaced by the low molecular weight heparins (LMWHs). LMWHs such as the Enoxaparin and Dalteparin are commonly used for the management of acute coronary syndrome. These drugs have been approved for the treatment of unstable angina and are currently undergoing rigorous trials for interventional indications. Arixtras is also developed for various subcutaneous indications. However, it exhibits lower anticoagulant effects and may not be optimal for intravenous and interventional purposes. At a higher dosage when administered intravenously the LMWHs produce varying degrees of anticoagulation at relatively lower activated clotting times . Several studies in vascular and cardiovascular interventions have shown that even at a relatively lower anticoagulant level the LMWHs are as effective as unfractionated heparin at the recommended dosages which produce a relatively higher level of anticoagulation (ACT > 200 secs.). Thus, these agents are currently developed for interventional and surgical indications. It should be emphasized that different LMWHs produce different degrees of anticoagulation and should therefore be individually optimized for a given interventional or surgical purposes. At a relatively high dosage the levels of LMWHs can be measured by using the ACT and APTI. When administered with such GP Ilb/Illa inhibitors as the Abciximab, Aggrastat or Eptifibratide, these drugs may require dosage adjustment.
However, since the introduction of the front loading of Clopidogrel, the unqualified use of GP IIb/IIIa is debated. LMWHs will find expanded indications in both the medical and surgical management of patients with cardiovascular disorders including atrial fibrillation and congestive heart failure. The only approved anti-Xa drug is represented by a synthetic heparinomimetic, namely, Arixtraa. This drug is given for the prophylaxis of post orthopedic indications. This agent is undergoing additional clinical trials in the management of coronary artery diseases. Because of the dependence on antithrombin III (AT) and the sole anti-Xa effects, it has a narrow therapeutic index and its efficacy in this indication may be limited. Additional clinical trials are needed at this time to validate the clinical potential of this drug. The antithrombin agents (Hirudin, Hirulog and Argatroban) were initially developed for arterial indications. However, these agents are approved as a substitute anticoagulant in patients with heparin induced thrombocytopenia (HIT) and PCI. Currently all of these agents are being developed for surgical and interventional use. However, since there is no available antidote at this time, the development is somewhat limited. The antithrombin agents may be useful in patients with HIT which require further clinical validation. Many other anti-Xa agents are also developed. Most of these can be given parenterally. However, the clinical data is somewhat limited. Similarly, several of the new antiplatelet drugs can be administered parenterally and may be useful in CAD. Since most of these newer anticoagulant and antithrombotic drugs are mono-therapeutic their therapeutic index is rather limited. Only in combination these agents can mimic heparins. At this time it is safe to state that heparin and its LMW derivatives will remain the anticoagulant of choice for cardiovascular indications until these newer agents have been validated in extended dinical trials in polytherapeutc settings.
Over the past decade, interest in anticoagulant and thrombolytic drugs has grown dramatically as evidenced by a continual increase in the number of drugs introduced for preclinical and clinical development (1) (2) (3) (4) (5) (6) . As shown on Fig. 1 Due to these rapid developments, several important issues related to current practices in anticoagulant/antithrombotic therapy are recognized. These issues include:
1. The replacement of unfractionated heparin by low-molecular-weight heparins in all indications.
2. The potential replacement of heparins by newly developed antithrombin and anti-Xa agents.
3. The feasibility of oral anti-Xa and anti-Ila agents as potential substitutes for oral anticoagulant drugs.
4. The development of synthetic heparinomimetics representing specific activities of heparins and their relative bioequalence to heparin. 5. The development of recombinant antithrombotic agents such as the activated protein C (APC), tissue factor pathway inhibitor, recombinant equivalent of serpins and thrombomodulin, with reference to their relative applications in specific disorders.
6. The development of newer antiplatelet drugs such as the adenosine diphosphate (ADP) receptor inhibitors, glycoprotein IIb/IIIa receptors, phosphodiesterase inhibitors, and specific COX-1 and COX-2 inhibitors and their relevance in the management of various disorders. The relevance of on-board aspirin for the therapeutic index of each of these agents also requires additional investigations.
7. The design of newer thrombolytic agents, with specific reference to their endogenous interaction and pharmacodynamic differences in terms of their relative clinical effects in stroke and myocardial infarction.
8. The recent recognition of the antithrombotic actions of statins, nitric oxide donors, and other non-anticoagulant drugs and their impact on overall therapeutic approaches.
Despite several limitations heparin is still the most widely used anticoagulant in the United States. Several oral formulations of heparin have been developed and tested in clinical trials. Although effective, the oral formulations of heparin failed to exhibit comparable efficacy in the management of deep venous thrombosis (DVT). In addition, several other chemically modified forms of heparin did not exhibit the expected pharmacologic effects in the preclinical and clinical settings. The LMWHs represent an optimal approach of using heparin components. It may be that the oral formulations exhibit efficacy in other indications. Additional studies in modified and improved formulations are in progress at this time.
While heparin remains the sole anticoagulant used for cardiovascular surgical procedures, the continual expansion of the newer applications of LMWH has added a new dimension to the overall management of thrombotic and cardiovascular disorders. Evidently, the LMWHs have achieved gold standard status in the management of thromboembolic disorders and now challenge other treatments, such as oral anticoagulants, for various indications. Several recent clinical trials have provided supportive data for the polytherapeutic use of LMWHs in the management of coronary syndromes, thrombotic stroke, and malignancy associated with thrombotic events. LMWHs have also shown efficacy as surgical and TFPI interventional anticoagulants. Unlike heparin, these drugs exhibit a better therapeutic index in these indications. LMWHs are also recently evaluated in atrial fibrillation and cardiac transplantation. These drugs represent a refined use of heparins. Being pharmacologic in nature, the LMWHs have multiple sites of action. Their actions are not only limited to the inhibition of coagulation enzymes but these drugs exhibit profound actions on endothelial sites and blood cells. This has led to the development of the nonanticoagulant forms of LMWHs.
Antithrombin agents such as hirudin and hirulog also have been compared with LMWHs for postoperative prophylaxis of thromboembolism. Initial reports indicate favorable results with the use of recombinant hirudin for treatment of coronary syndromes. However, safety issues such as bleeding were a major concern for the regulatory agencies. In addition to the development of LMWHs, understanding the mechanisms of their antithrombotic actions and the relevance of their structural components has led to the development of synthetic analogs of heparin fragments. One remarkable approach based on the elucidation of the structure of heparin has led to the synthesis of oligosaccharides with high affinity for antithrombin III (AT). A synthetic pentasaccharide has undergone extensive clinical trials for both thromboembolic and coronary indications. Although the development of the synthetic pentasaccharide represents a major advance in producing heparin-like drugs by using synthetic organic methods, these agents only represent a single pharmacologic action of heparin. Furthermore, the pharmacologic actions of these glycosamimetics depend on endogenous antithrombin. The US FDA and the EMEA have recently approved the use of synthetic heparin pentasaccharide namely, Arixtra (fondiparinaux) for the management of post-orthopedic surgical thrombosis. However, bleeding risk has been unexpectedly higher with this drug and its use is not recommended in underweight patients. Pentasaccharide may likely be equivalent to other modalities in the management of DVT prophylaxis; however, its use in other indications where LMWHs are approved may not provide equivalence or superiority. Several additional clinical trials are currently being carried out with pentasaccharide in multiple indications including treatment of thrombosis. In addition to the lack of a clear clinical response, other issues, such as bleeding, non-availability of an antidote, drug interactions, product accumulation, and thrombo-cytopenia represent some of the issues that will require more clear clarifications. Current clinical trials may provide some of the answers regarding these issues.
There is much discussion of how LMWHs and related drugs mediate their effects. In addition to potentiation of AT, several other mechanisms have been identified, including the release of tissue pathway inhibitor (TFPI), vascular effects, profibrinolytic effects, platelet selectin modulation, and growth factor modulation. Recently published data also suggest that LMWHs may downregulate thrombin activatable fibrinolytic inhibitor (TAFI). This validated the initial observations that heparins exhibit profibrinolytic effects.
Clinical trials in Europe have shown that subcutaneous LMWH, given once or twice daily, is at least as safe and effective as continuous intravenous heparin in the prevention of recurrent venous thromboembolism and is associated with reduced bleeding and lower mortality rates. Several recent studies have shown that home administration of fixed-dose subcutaneous LMWH is as safe and effective as hospital administration of intravenous heparin in patients with proximal venous thrombosis. Also, initial evidence clearly suggests that LMWH may be a useful alternative to heparin in patients with pulmonary embolism. LMWHs also may be useful alternatives to heparin for arterial indications, such as treatment of unstable angina or stroke and for maintenance of peripheral arterial grafts. Recognizing the utility of LMWHs, the pharmaceutical industry has focused its attention on their use in the management of ischemic and thrombotic stroke. The initial results of clinical trials are promising. Thus, in the near future, the use of LMWH for prevention of thrombotic or ischemic stroke will be an important goal. LMWHs have also shown efficacy in vascular dementia of Alzheimer's type (SDAT). Thus, these drugs may become useful in neurologic disorders. The success of early clinical trials also suggests that LMWH may be useful in the management of primary and secondary ischemic or thrombotic stroke. In several clinical trials, LMWHs did not show any improvement for outcome in stroke. However, these drugs showed a clear reduction in the incidence of thrombotic complications in ischemic stroke patients.
Although LMWHs are proving to be as effective as and safer than heparin for various indications, it is important to realize that differences in the manufacturing process of various LMWHs leads to differences in the pharmacologic pro-files. Although these differences have not been clinically validated, each of the LMWHs is expected to exhibit its own therapeutic index in a given clinical setting. Thus, the interchange of LMWHs based on equivalent gravimetric or biologic potency of standardized dosages may or may not be feasible. Optimized dosages of various LMWHs have been established for prophylaxis and treatment of DVT. Thus, each agent is given at a specified dose. The optimized dosage of different LMWHs also differs for the management of acute coronary syndrome. The most notable differences are observed at higher doses. When these agents are given intravenously for interventional cardiovascular procedures, each of the LMWHs produces a different anticoagulant response regardless of the dosage equivalence at the gravimetric or bioassay adjusted potency. Therefore, the US FDA, World Health Organization, and professional organizations consider each drug to be distinct.
Because of the newer indications and length of therapy, additional issues related to the optimal use of LMWHs remain to be addressed. Examples include monitoring, control of bleeding, and drug interactions. In addition, the use of high-dose subcutaneous LMWHs may require pharmacologic antagonism. Several clinical trials have been designed to obtain information related to these issues. The differential clinical efficacy of various LMWHs was evident in the trials carried out with dalteparin (FRISC and FRIC), enoxaparin (ESSENCE), nadroparin (FRAXIS), and similar clinical trials.
The LMWHs have also shown remarkable clinical efficacy in the management of cancer-associated thrombosis. In addition, these drugs have recently reduced the mortality in cancer clinical trials carried out in cancer patients. Thus, besides the anticoagulant effects, there may be additional actions of these agents that warrant further investigation. Currently, several large scale clinical trials are in progress to evaluate the safety and efficacy of LMWHs in malignancy and related disorders.
Economic analyses of the treatment cost of heparin vs. LMWH in various clinical settings show that although the cost of LMWH is marginally higher than the cost of heparin ($40-$150), the expected reduction in costs for all treatment-related clinical events is much higher for LMWHs ($350-$2700) than for heparin. Thus, LMWHs are an attractive alternative in an era of managed care reform. Individual economic analysis for specific indications may provide additional in-formation about reduced costs with the use of LMWHs for long-term outpatient treatment of such syndromes as unstable angina and ischemic cerebral events.
Additional depolymerization of LMWHs has resulted in the development of ultra-low LMWHs. Several ultra LMWHs have recently become available and are currently developed for specific indications. Bemiparin represents such a product that has been found efficacious in the management of DVT in European trials. Several other agents are clinically tested in some indications as vascular dementia, inflammatory bowel disease, and acute coronary syndromes.
Understanding the coagulation process has led to the identification of thrombin as a key enzyme in the thrombogenic processes. Several direct thrombin inhibitors have been developed over the past few years by different methods. Argatroban (Novastan'), hirulog (AngiomaxO), and hirudin (Refludan®) have become available.
The recognition of heparin-induced thrombocytopenia as the most catastrophic adverse effect of heparin has led to the use of alternate anticoagulants. The antithrombin agents are most useful in this indication and have been specifically developed for heparin-induced thrombocytopenia (HIT). Hirudin, the leech-derived protein, has been compared with heparin for various indications in numerous clinical settings, including treatment and prophylaxis of venous and arterial thrombotic disorders. The use of hirudin has been reported to be associated with an increased risk of bleeding, indicating that better monitoring and dose-adjustment protocols are needed as are effective antidotes. So far, clinical trials comparing hirudin and heparin as adjuncts in thrombolytic therapy in myocardial infarction (TIMI 9B) and acute coronary syndromes (GUSTO Ilb) have shown hirudin to be marginally (if at all) superior to heparin. Recently several reports comparing the effects of heparin and hirudin on various parameters have become available. A study comparing heparin and recombinant hirudin for the prophylaxis of DVT provided impressive data in favor of hirudin. In a second study, LMWHs were compared with hirudin for post-surgical prophylaxis of DVT. The results favored hirudin. Both studies emphasize an important point about the validity of well-designed clinical trials. It is important to understand that the efficacy and safety of a new drug may not be determined by trials for a single indication. Therefore, additional clinical trials are needed for various specific indications.
Hirulog represents a designer antithrombin drug that combines the features of hirudin and other anticoagulant peptides. It is a reversible antithrombin agent and offers several advantages over hirudin. The FDA has approved this agent for percutaneous transluminal coronary angioplasty (PTCA). Currently, this is undergoing clinical trials for cardiovascular bypass surgery. Furthermore, antithrombin agents such as Argatroban and hirulog may be useful in offpump bypass surgery.
Argatroban, another smaller thrombin inhibitor of the peptidomimetic type is also approved by the US FDA for the alternate anticoagulation treatment of patients with HIT. It has been used successfully in Japan for longer than a decade in the treatment of thrombotic disorders. It also represents the very first clinically used antithrombin agent. Several clinical trials in both Europe and the US have been designed to investigate its use as alternative to heparin in heparincompromised patients and as a prophylactic agent to reduce late restenosis after PTCA and coronary directional atherectomy (CDA). Argatroban was successfully used for the management of anticoagulation in patients with heparininduced thrombocytopenia and as a substitute for heparin in PTCA. Because the half-life of argatroban is rather short, it has been administered via infusion protocols. For therapeutic anticoagulation, a level of 1 to 2 gg/mL is indicated, whereas for interventional cardiology procedures a level of 3 to 7 ,ug/mL is necessary. Argatroban also exhibits additional actions on blood vessels and may exert its clinical effects via multiple measures. Unlike hirudin, Argatroban is a reversible antithrombin drug. Furthermore it exhibits additional pharmacologic actions that are not related to its antithrombin effects.
Another area of aggressive basic and clinical research is the development of oral thrombin inhibitors. Ximelagatran represents a prodrug version of a direct thrombin inhibitor, melagatran.
This antithrombin drug has been evaluated in various thrombotic indications. Although this orally administered drug is effective, there are several safety issues related to its use. Many other agents such as MC-977 (Mitsubishi) are in clinical development.
Because of their weaker anticoagulant effects in global clotting tests, direct factor Xa inhibitors were not considered desirable anticoagulant and antithrombotic agents for developmental purposes. However, because of favorable clinical results with pentasaccharide strong interest in syn-thetic anti-factor Xa drugs has reemerged. These agents may be useful in the prophylaxis of both arterial and venous thrombotic disorders and may offer a greater margin of safety than existing drugs. Additional advantages of direct thrombin and factor Xa inhibitors over heparin include subcutaneous and oral bioavailability. Although their biologic half-life is usually less than 30 minutes, coupling to larger agents such as dextran or albumin can prolong their half-life without affecting their pharmacologic actions. Questions about monitoring and effective antidotes/antagonism will have to be answered before thrombin and factor Xa inhibitors can be widely explored in clinical settings. Depending on their specificity for thrombin or factor Xa, they may be used as adjuncts with other classes of drugs, such as thrombolytic agents for treatment of acute myocardial infarction. Low-molecular-weight thrombin and factor Xa inhibitors also may be used for localized delivery, stenting, and transdermal delivery.
Several oral factor Xa inhibitors are also under clinical trials in various thrombotic indications. The oral bioavailability of the drugs widely varies and not all of the clinical effects are directly related to the inhibition of factor Xa. Furthermore, these drugs do not inhibit the preformed thrombin. Thus their use may be limited to prophylactic indications. At this time, several anti-Xa drugs are currently developed in various indications. A major interest in the area is to develop oral anti-Xa drugs that can be used for the long-term management of both arterial and venous thrombosis. Because of their better bioavailabilty, thrombin and factor Xa inhibitors in combination may be more useful than the single agents. Optimal combinations for specific indications may be considered. As in the clinical development of LMWHs, thrombin and factor Xa inhibitors should be compared with heparin in terms of safety, efficacy, and cost.
Some of the important issues related to the current practices on anticoagulant therapy are listed in the following. In the search for antiplatelet agents to be used as antithrombotic drugs, it was recognized that the platelet glycoprotein lIb/Illa (GPIIb/IIIa) plays a key role in the final common pathway for platelet aggregation. Several reports have become available recently. Many synthetic GPIIb/IIIa inhibitors are currently under clinical development for various indications. In the EPIC trial, ReoPro (an anti-GPIIb/IIIa) has been shown to reduce thrombotic events after PTCA. In an EPILOG study, the combined effects of ReoPro and heparin resulted in inhibition of restenosis. Many of the GPIIa/IIIb inhibitors, including ReoPro, also have been found to inhibit the vitronectin receptor (V<i3 integrin), which is implicated in endothelial and smooth muscle cell migration. Thus, these agents exhibit multiple effects in addition to their antiplatelet functions. Another application of GPIIb/IIIa inhibitors as alternative agents to aspirin in the management of unstable angina, non-Q wave myocardial infarction, and ischemic or thrombotic stroke. The mechanism of the antiplatelet action of synthetic GPIIb/IIIa inhibitors and antibodies may be the same; however, major differences have been noted in their safety and efficacy. An emerging problem is therapeutic monitoring, which is being addressed with pointof-care systems. Thus, major clinical breakthroughs are expected with the use of these inhibitors in the management of cerebrovascular and cardiovascular disorders.
The introduction of novel antiplatelet drugs has added a new dimension to the management of arterial thrombosis in particular, thrombotic stroke. The availability of specific antagonist of ADP receptor (e.g., ticlopidine) has provided a new approach for several cardiovascular and cerebrovascular indications. The second-generation ADP receptor-blocking agents (e.g., clopidogrel) underwent extensive clinical trials to assess their therapeutic efficacy in combined cardiovascular and cerebrovascular endpoints. The comparative results reported in several recent clinical trials have favored clopidogrel. However, in most of these studies on-board aspirin has been used. Clopidogrel has also been proven to be very important in preventing in-stent thrombosis.
Newer developments in thrombolytic therapy include recombinant tissue plasminogen activa-tors (t-PAs). Bolus-indictable Reptiles is an unglycosylated plasminogen activator consisting of the Kringle 2 and protease domain of t-PA with a threefold to fourfold longer half-life than t-PA. The INECT trial demonstrated that Reptilase is superior to streptokinase for management of heart failure. Difference variants of wild-type (wt) t-PA, recombinant staphylokinase, and RTSPocl and (vampire bat t-PA) also have undergone clinical trials. Recombinant urokinase and prourokinase are now expressed in mammalian cell lines and are undergoing active clinical development. Molecular engineering of recombinant t-PA has extended the biologic halflife for bolus dosing, whereas staphylokinase and vampire bat plasminogen activator exhibited fibrin specificity. Additional clinical studies on agents such as the Reteplase, Teneteplase, Lenoteplase, Monteplase, Parmitplase, and several other newly bioengineered agents have recently become available. Thrombolytic agents also have found a place in the management of acute thrombotic stroke. The US FDA has approved recombinant t-PA for these indications. However, caution should be exercised in dosing these agents. Optimal approaches to improve the safety/efficacy index are currently under investigation. The next few years will witness the emergence of longer-acting thrombolytics to facilitate bolus dosing and improved specificity for fibrin and other receptors to target thrombotic sites. New indications for thrombolytic therapy, such as stroke and microangiographic syndromes, will be pursued. Thrombolytic agents have also been used with LMWHs and antiplatelet drugs to produce improved outcomes in specific indications.
Restenosis after cardiac interventions remains
a major challenge. An optimal therapeutic approach is still unavailable despite major scientific and financial undertakings. Even with the introduction of newer interventional cardiovascular and peripheral vascular procedures, late restenosis is commonly seen at a rate of 10% to 60%. Although the claimed efficacy of cardiovascular interventions exceeds that of medical and surgical approaches, restenosis is a major problem, resulting in angina and myocardial infarction. Several newer anticoagulant and antithrombotic drugs have been used to reduce restenosis. However, these approaches have been met with limited success. Recent results with GPIIb/IIIa-targeting antibodies have been encouraging. With a better understanding of pathophysiology of restenosis, improved drugs can be developed. Anticoagulant drugs such as LMWHs and PEG hirudin may prove useful. Mechanical devices such as stents and localized and programmed delivery of drugs may be expected to improve outcomes. Although monotherapy may be useful in the control of abrupt closure and subchronic occlusion, its role in late restenosis may be limited. Combined pharmacologic and mechanical approaches, coupled with specialized delivery, already have provided favorable results. In this regard, heparin-coated stents and combination therapy using clopidogrel have provided excellent results.
The coming year will witness dramatic developments in the management of thrombotic and cardiovascular disorders. Synthetic and recombinant approaches will provide cost-effective and clinically useful drugs. LMWHs and synthetic heparin analogs are expected to have significant effects on the overall management of thrombotic and cardiovascular disorders. Factors such as managed care, regulatory issues, polytherapy, and combined pharmacologic and mechanical approaches will redirect the focus in management of DVT thrombobembolism, myocardial infarction, and thrombotic stroke. The direct antithrombin agents such as hirudin and PEG hirudin will be of great value for surgical anticoagulation and various acute indications. Post-surgical control of thrombotic processes may require combination therapy and heparin-derived agents, such as pentasaccharide, and non-heparin gylcosaminogylcans, such as dermatan sulfate. Biotechnology-derived heparin analogues will also be developed.
Despite these significant developments, conventional drugs such as heparin, LMW heparins, oral anticoagulants, and aspirin will remain the gold standard of treatment despite their known drawbacks. However, optimized dosing of combined therapy and use of adequate monitoring techniques will provide additional important approaches for the use of conventional drugs. Upon further optimization these drugs can be used for various additional indications in a cost-effective manner. The newer drugs however provide alternatives that in the next few years may lead to improved, cost-effective, and targeted treatments. The antithrombotic actions of the non-anticoagulant drugs such as the cholesterol-lowering agents (statins), specific inhibitors of cyclooxygenase, drugs capable of donating nitric oxide or upregulating its mediators, and drugs modulating endothelial function will also impact combination therapy for thrombotic and cardiovascular diseases.
It is therefore important to include these newer developments in educational and training clinical community is challenged with these continual developments and has the ultimate responsibility to provide optimal approaches in the management of thrombotic disorders. The clinical efficacy of safety and newer drugs in comparison to the current standard of care requires an objective validation. Therefore only parallel clinical trials can provide such information. Unilateral endorsement of the use of newer agents such as the antithrombin/anti-Xa drugs, single targeting oligosaccharides, and recombinant proteins is not justified at present. While these agents provide unique tools to investigate thrombogenesis in its control their relative clinical potential requires proper validation. Thrombosis is a polypathologic syndrome requiring drugs with multiple targets, thus it would be unlikely to have monopharmacologic agents as the agents of choice in the management of this complex pathologic process.
FUTURE PERSPECTIVES
UFH will continue to be used for interventional and surgical indications until the newly developed anticoagulant agents are shown to have clinical superiority over this drug. LMWHs will replace UFH for most of the subcutaneous indications and can be developed for interventional use; however, for surgical indications these agents may not be optimal until an antidote is developed. While the newly developed anticoagulants are structurally and biologically well defined, it is unlikely that these drugs can replace heparin for all indications.
